SPIMACO

2070.SRPre-clinical

Riyadh, Saudi ArabiaFounded 1986spimaco.com.sa

SPIMACO is a major player in the Saudi and MENA region pharmaceutical market, established to enhance local drug manufacturing capabilities and ensure medicine security. The company operates multiple manufacturing facilities and has a diverse portfolio spanning various therapeutic areas, including cardiology, gastroenterology, and antibiotics. As a publicly listed entity, it plays a strategic role in the Saudi Vision 2030 goals for healthcare self-sufficiency, combining local production with technology transfer from international partners.

Market Cap

$3.4B

Founded

1986

Employees

1000-3000

Focus

Biotech

2070.SR · Stock Price

USD 28.88+0.00 (+0.00%)

Historical price data

AI Company Overview

Technology Platform

Large-scale, integrated pharmaceutical manufacturing platform for generic drugs, including API production, formulation development, and GMP-compliant production of solid, liquid, sterile, and inhalable dosage forms.

Funding History

IPOUndisclosedUndisclosedJan 27, 2008

Opportunities

Significant growth opportunity driven by Saudi Arabia's 'Vision 2030' mandate to localize pharmaceutical production, aiming for 40% of total drug market.

Expansion into complex generics, biosimilars, and exports to GCC and MENA markets presents additional avenues for growth.

Risk Factors

Faces regulatory pricing pressures from government tenders, intense competition in the generics market, supply chain vulnerability for imported raw materials, and execution risks associated with the national localization strategy's pace and scale.

Competitive Landscape

Competes with other local Saudi manufacturers (Jamjoom, Tabuk) and multinational generics firms (Sandoz, Hikma). Differentiates through its scale of local manufacturing, strategic importance to national drug security, and strong government procurement relationships.

Publications